Kloxxado Spray
Product Images NDC 59467-679

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Kloxxado (NDC 59467-679). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Specialty Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Peeling-back-blister-with-zoom-of-triangle (Image 01)

An instructional illustration showing hands peeling back a protective seal from a KLOXXADO (naloxone HCl) nasal spray package. A zoomed inset focuses on the product labeling, highlighting the brand name KLOXXADO, the active ingredient naloxone HCl, the strength of 8 mg/0.1 mL, and partial usage instructions indicating nasal route and dosage.*

FDA Label Image

Figure-1(a)-naloxone-hcl-ns-8mg-with-stand-dev (Image 02)

Pharmacokinetic line graph depicting mean naloxone concentration in plasma (ng/mL) over time (hours) for different administration routes and dosages, including nasal spray 8 mg, intravenous injection 2 mg, and intramuscular injection 0.4 mg from two studies (Study I and Study II). The graph shows concentration changes up to 4 hours post administration with error bars for variability.*

FDA Label Image

Figure-1(b)-naloxone-hcl-ns-8mg-with-stand-dev (Image 03)

A pharmacokinetic line graph comparing mean plasma concentrations of naloxone (ng/ml) over time (hours) for different routes of administration: nasal spray 8 mg (two studies), intravenous injection 2 mg, and intramuscular injection 0.4 mg (two studies). The graph includes error bars and distinct markers for each administration type to depict variation over a 0.5-hour period.*

FDA Label Image

Kloxxado-fc-c50001063-02-k03 (Image 04)

An instructional illustration showing a hand holding a nasal spray device, with labeled parts including the nozzle and plunger. This likely demonstrates the proper way to use the spray.*

FDA Label Image

Ifu-image-2-proper-way-to-hold-device (Image 05)

An instructional black-and-white line drawing showing a person lying down while another person is administering KLOXXADO nasal spray into one nostril, with one hand holding the nasal spray device and the other supporting the patient's head from behind.*

FDA Label Image

Ifu-image-3-support-back-of-neck (Image 06)

An instructional line drawing showing the use of a nasal spray device. The illustration depicts a hand holding the spray applicator, administering a spray into a nostril, indicating the proper technique for nasal spray administration.*

FDA Label Image

Ifu-image-4-insert-tip-into-nostril (Image 07)

An instructional diagram showing a person lying on their side with one knee bent to prevent rolling onto the stomach and one hand supporting the head. The image includes labels explaining these body positions.*

FDA Label Image

Ifu-image-5-place-patient-on-their-side (Image 08)

An illustration of a circular timer depicting a 2-3 minute interval, with a highlighted segment representing the elapsed time. This figure could be used in instructional content related to KLOXXADO nasal spray for naloxone HCL.*

FDA Label Image

Ifu-image-6-clock-2-3-minutes (Image 09)

Packaging label for KLOXXADO (naloxone HCl) nasal spray 8 mg by Hikma Specialty USA Inc. The label includes usage instructions for opioid overdose, a two-pack box indication, and warnings such as not testing the device before use. The packaging is predominantly white with orange and green text, including barcodes and product NDC 59467-679.*

FDA Label Image

Image 10

KLOXXADO nasal spray 8 mg label for naloxone HCL by Hikma Specialty USA Inc. The label specifies the dosage form as nasal spray, intended for nasal use with one spray per unit. It includes storage instructions and cautions, and prominently states it is for known or suspected opioid overdose. The label features the product NDC 59467-679-01 and the Hikma logo.*

FDA Label Image

Image 11

KLOXXADO (naloxone HCL) nasal spray 8 mg label featuring an orange background and white text. The label includes the product name, strength, and route of administration along with the NDC number 59467-679-01, and usage instructions indicating use in the nose only. The labeler is Hikma Specialty USA Inc.*

FDA Label Image

Image 12

Packaging label for KLOXXADO nasal spray containing 8 mg/0.1 mL of Naloxone HCL. The label shows a predominantly orange background with the Hikma Specialty USA Inc. logo in white on the left side and a barcode at the top center. The label design is curved to fit the spray device.*

FDA Label Image

Image-chemical-structure-usp.jpg (Image Chemical Structure Usp)

Chemical structure diagram of Naloxone Hydrochloride Dihydrate (Naloxone HCl .2H2O), showing rings, functional groups, and stereochemistry as part of the active ingredient in KLOXXADO nasal spray.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.